Latest studies
- RecruitingPHASE2, PHASE3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
This study looks at a new medicine called ponsegromab for advanced pancreatic cancer that has spread, especially when patients have lost a lot of weight and feel very tired. It aims to see if adding ponsegromab to standard chemotherapy helps more than chemotherapy alone.
CachexiaMetastatic Pancreatic Ductal AdenocarcinomaBulgaria - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney DiseaseBulgaria - RecruitingPHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
This study compares a new medicine, Elecoglipron, to an existing one, Semaglutide, for adults with Type 2 Diabetes. It aims to see if the new drug is safe and effective for people whose diabetes isn't well-controlled and who have a higher risk of heart problems.
Type 2 Diabetes MellitusBulgaria - RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaBulgaria - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaBulgaria - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]Bulgaria - Completed
Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with mild, moderate or severe skin conditions
Acne is a common skin condition that affects confidence and well-being. This study tests whether a daily skincare routine using Eucerin products helps clear mild to severe spots. Researchers want to see how well these creams work over a year in people aged 12 to 50 across the UK and worldwide.
Subjects with acne-prone skin aged 12-50 years with Investigator's Global Assessment (IGA) grades 2-4, evaluating treatment of mild to severe acne vulgaris.Bulgaria - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseBulgaria - RecruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER 01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease
This clinical trial is testing a new inhaled medicine called Fexlamose for adults with moderate to severe chronic obstructive pulmonary disease (COPD). Researchers want to see if breathing in this liquid medicine for four weeks improves lung function, clears mucus from the airways, and helps people breathe more easily.
Chronic Obstructive Pulmonary DiseaseBulgaria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
This clinical trial is studying a medicine called crinecerfont for adults with classic congenital adrenal hyperplasia (CAH). CAH causes the body to make too much male hormone. Researchers want to see if this daily medicine can safely lower these hormone levels over 24 weeks without needing high steroid doses.
Classic Congenital Adrenal Hyperplasia (CAH)Bulgaria - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
This study is testing a new tablet called CRD-4730 for adults with heart failure. Researchers want to see if the medicine can help the heart pump blood better, ease everyday symptoms, and improve quality of life. Participants will take either the study drug or a dummy pill for 24 weeks.
heart failureBulgaria - AuthorisedTherapeutic exploratory (Phase II)
Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
This study tests a new injection called vortosiran to see if it can safely prevent blood clots. It is for adults who have had a blood clot in the past, or people with cancer who have a high risk of getting one. Researchers want to see how it affects clotting proteins.
Venous ThromboembolismBulgaria - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
This study tests a medicine called Vyvgart in adults with Sjögren's disease who have nerve damage in their hands, legs, or feet. Researchers want to see if regular injections under the skin can ease nerve symptoms, reduce fatigue, and be used safely compared with a dummy treatment.
Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)Bulgaria - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
This study is testing a new tablet called ENV-294 for adults living with moderate-to-severe atopic dermatitis, also known as eczema. Researchers want to see if different doses of this medicine can calm inflamed skin, reduce itching, and remain safe and gentle for people to take.
Atopic DermatitisBulgaria - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
This clinical study tests an experimental tablet called soquelitinib for adults with moderate to severe atopic dermatitis, also known as eczema. Researchers want to see if the medicine is safe, easy to take, and able to reduce skin redness, dry patches, and itchy symptoms compared to a dummy tablet.
Atopic dermatitis (AD)Bulgaria - AuthorisedTherapeutic exploratory (Phase II)
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)
This study tests a new daily tablet called AC01 for people with long-term heart failure. Researchers want to see if this medicine can help the heart pump blood more effectively. Participants take either the real medicine or a dummy tablet for 12 weeks while doctors monitor their heart health.
chronic advanced heart failure with reduced ejection fraction (HFrEF)Bulgaria - AuthorisedTherapeutic confirmatory (Phase III)
LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy
This study tests a new medicine called cenerimod for adults with lupus and active kidney inflammation (lupus nephritis). Researchers want to see if adding cenerimod to standard treatments helps protect the kidneys, reduces protein in the urine, and lowers the need for steroid medicines over 76 weeks.
Systemic lupus erythematosus and active lupus nephritisBulgaria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
This study tests a new medicine called claseprubart (DNTH103) for generalised myasthenia gravis, a condition that causes muscle weakness. Researchers want to see if the medicine safely improves muscle strength and helps with daily activities compared to a dummy drug (placebo) in adults aged 18 and older.
generalized Myasthenia gravisBulgaria - AuthorisedTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
This 52-week clinical study is testing an experimental medicine called EXPD-101 for adults living with COPD. Researchers want to find out if taking this treatment can safely reduce chest flare-ups, ease breathing symptoms, and help people stay out of hospital compared with a dummy treatment (placebo).
Chronic Obstructive Pulmonary Disease (COPD) exacerbationsBulgaria - AuthorisedTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjögren’s Disease
This study tests a new injection called telitacicept for adults with active primary Sjögren's disease. Researchers want to see if this medicine works better and is safer than a dummy treatment (placebo) at lowering general disease activity, easing dryness, and improving daily symptoms over 48 weeks.
Active Primary Sjögren’s DiseaseBulgaria - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study)
This study tests a new injection called plozasiran in adults with high levels of blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fats over one year compared to a dummy jab (placebo). This could help reduce risks to the heart and pancreas.
HypertriglyceridemiaBulgaria - RecruitingTherapeutic confirmatory (Phase III)
An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
This study follows children who received eye treatment for retinopathy of prematurity (ROP) in an earlier trial. Researchers want to see how their eyesight, eye structure, and general development progress as they grow up. The goal is to ensure the treatment is safe and effective in the long run.
Retinopathy of prematurity (ROP)Bulgaria - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)
This Phase 3 clinical study tests a new injection called plozasiran for adults with very high blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fat levels over 12 months compared to a dummy jab, reducing the risk of painful pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Bulgaria - RecruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
This clinical trial is testing a new injection called efgartigimod for adults with inflammatory muscle disease (myositis). Researchers want to see if the medicine can safely reduce muscle inflammation, improve strength, and help people lower their daily steroid dose compared to a dummy treatment over 52 weeks.
Active Idiopathic Inflammatory Myopathy (IIM)Bulgaria - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)
This phase 3 study tests a new treatment called UGN-103 for non-muscle invasive bladder cancer. UGN-103 is a medicine placed directly into the bladder to help clear early-stage cancer cells. Researchers want to see how well it works, how safe it is, and if it can reduce the need for surgery.
Nonmuscle Invasive Bladder CancerBulgaria - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, multinational, multicenter, randomized, double blind, placebo controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn’s disease.
This clinical study tests a new medicine called balinatunfib (SAR441566) for adults with moderate to severe Crohn's disease. Researchers want to see if different doses help heal the bowel lining and reduce symptoms compared to a dummy treatment (placebo), while checking for any unwanted side effects.
Crohn's diseaseBulgaria - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema
This clinical trial is testing a new daily tablet called deucrictibant for adults with hereditary angioedema (HAE). Researchers want to find out if taking this tablet can safely prevent painful swelling attacks. Participants will take either the study tablet or an inactive dummy pill for 24 weeks.
Hereditary AngioedemaBulgaria - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseaseBulgaria - RecruitingTherapeutic confirmatory (Phase III)
BRISOTE: A Multicentre, Randomised, Double-blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist
This clinical trial is testing whether an injection called benralizumab can help adults with severe eosinophilic asthma. Researchers want to see if adding this medicine to standard daily inhalers reduces asthma attacks and improves everyday breathing over 48 weeks compared to standard inhaler treatments alone.
Eosinophilic AsthmaBulgaria - RecruitingPhase II and Phase III (Integrated)
C4671026-A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID-19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE
This study looks at an antiviral medicine (nirmatrelvir and ritonavir) for children and young people with COVID-19. Researchers want to find out how safe the medicine is, how the body handles it, and whether it stops mild COVID-19 from turning into severe illness in vulnerable young patients.
SARS-CoV-2 InfectionBulgaria - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
This clinical study tests two new medicines, REGN7508 and REGN9933, for adults with atrial fibrillation (an irregular heartbeat). It aims to find out if these treatments can safely stop blood clots and strokes in people who cannot take standard blood-thinning tablets due to a high risk of bleeding.
Atrial Fibrillation (AF)Bulgaria - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with advanced prostate cancer
This Phase 2 trial tests a slow-release injection called Debio 4228 for men with advanced prostate cancer. The drug works by lowering testosterone, a hormone that fuels prostate cancer growth. Researchers want to find the safest and most effective dose, measure drug levels, and monitor side effects.
advanced prostate cancerBulgaria - RecruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
This study tests a new tablet version of mesalazine for people with mild to moderate ulcerative colitis. Researchers want to see if it is just as safe and effective as an established treatment at calming gut inflammation and helping symptoms settle down after eight weeks of daily treatment.
Ulcerative colitisBulgaria - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
This clinical trial is testing whether two medicines, pemafibrate and tofogliflozin, taken together can treat a severe fatty liver condition called NASH. The 48-week study aims to see if this combination safely lowers liver inflammation and prevents liver scarring from getting worse in adults without advanced liver damage.
Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver FibrosisBulgaria - RecruitingTherapeutic confirmatory (Phase III)
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
This two-year study looks at the safety of a medicine called cariprazine (Reagila) in teenagers aged 13 to 17 with schizophrenia. Researchers want to see how well young people tolerate the drug, monitor any side effects, and check if it helps improve their symptoms over time.
Adolescent patient (13-17 years of age) with SchizophreniaBulgaria - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
This study is testing a new medicine called rocatinlimab for adults with moderate-to-severe asthma. Researchers want to find the best dose and see if it cuts down asthma attacks that need steroid tablets or hospital care, while checking how safe and effective it is compared with a dummy medicine.
Moderate-to-severe AsthmaBulgaria - RecruitingHuman Pharmacology (Phase I)- Other
Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease
This study looks at an experimental medicine called Lu AG22515 for adults with moderate-to-severe Thyroid Eye Disease. Researchers want to see if the drug is safe and whether it can reduce eye bulging over 24 weeks, followed by long-term monitoring of the participants' health.
Active, moderate-to-severe TEDBulgaria - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)
This study tests a new injection called plozasiran for adults with very high blood fat levels, known as severe hypertriglyceridemia. Researchers want to see if the medicine can safely lower blood fats over one year compared to a dummy jab, reducing the risk of serious problems like pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Bulgaria - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a medicine called efgartigimod for adults with primary immune thrombocytopenia (ITP). ITP causes low blood platelets, leading to easy bruising and bleeding. Researchers want to see if an injection under the skin is safe and helps keep platelet counts at a healthy level over time.
Primary Immune ThrombocytopeniaBulgaria - Active not recruitingPHASE3
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
This study is looking at a new medicine called Ribupatide for people living with obesity. It compares Ribupatide with another medicine, Semaglutide, and a dummy treatment, to see how well it helps with weight loss. We want to find out if Ribupatide is more effective and safe.
ObesityBulgaria - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients
This study tests a new medicine called FYB206 for adults who have had advanced skin cancer (melanoma) removed by surgery. Researchers want to check if FYB206 behaves in the body in the exact same way as Keytruda, an approved immunotherapy drug used to help stop cancer returning.
Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resectionBulgaria - RecruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)
This study tests a new medicine called ianalumab for adults with active Sjögren's syndrome. Researchers want to see if regular injections can calm the immune system, ease severe tiredness, and improve dry eyes and mouth compared to a dummy jab (placebo) over 48 weeks of treatment.
Sjögren’s SyndromeBulgaria - AuthorisedHuman Pharmacology (Phase I)- Other
Comparative bioavailability study of Colistin Cyclops® administered as 3 different doses
This early-stage study looks at how the human body takes in an inhaled antibiotic called Colistin Cyclops. Researchers are testing three different doses in healthy adult volunteers to measure how much of the medicine enters the body and how quickly it breaks down.
No therapeutic indication in the current bioavailability trial with healthy adult participants.Bulgaria - RecruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
This study looks at a new drug called nemolizumab for adults with moderate-to-severe eczema (atopic dermatitis). Researchers want to see how safe the medicine is when used over a long period. They also want to find out how well it clears skin, calms itchiness, and improves sleep.
Atopic DermatitisBulgaria - AuthorisedTherapeutic use (Phase IV)
Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study
This study looks at whether an antidepressant called trazodone can reduce emotional numbness in adults with major depression. Emotional numbness means finding it hard to feel joy, sadness, or connection. Researchers will track changes in emotions, sleep, and everyday life over eight weeks of treatment with daily slow-release tablets.
Major depressive disorder (MDD)Bulgaria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients
This clinical trial looks at a new combination tablet for adults with high cholesterol who have never taken cholesterol medication before. Researchers want to see if combining two drugs (laroprovstat and rosuvastatin) lowers "bad" cholesterol better over eight weeks than taking either medicine alone or a dummy pill (placebo).
HypercholesterolaemiaBulgaria - AuthorisedPhase III and phase IV (Integrated)
A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)
This study is looking at a medicine called saroglitazar magnesium for people living with primary biliary cholangitis (PBC). Researchers want to see if this daily tablet can protect the liver from long-term damage, reduce extreme tiredness, and lower the risk of serious complications or needing a liver transplant.
Primary Biliary Cholangitis (PBC)Bulgaria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus
This clinical trial is testing a new medicine called AZD6234 for adults who are overweight or living with obesity. Researchers want to see if the drug helps people lose weight safely over 68 weeks, compared with a dummy treatment, in people who do not have type 2 diabetes.
Obesity or Overweight,Weight-Related Comorbidity,without Diabetes Mellitus, Type 2Bulgaria - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis
This study tests an experimental medicine called SAR441566 for adults with moderate-to-severe ulcerative colitis. Researchers want to see if different doses of this treatment can safely reduce bowel inflammation, relieve painful symptoms, and help bring the condition into remission compared to an inactive dummy treatment (a placebo).
Colitis UlcerativeBulgaria - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of LAD603 in patients with systemic lupus erythematosus
This clinical trial is testing a new study medicine called LAD603 for adults with systemic lupus erythematosus (lupus). Researchers want to find out how safe the medicine is and how well it helps calm lupus symptoms, especially skin problems, compared to a dummy treatment (placebo).
Systemic lupus erythematosusBulgaria